Wednesday, November 18, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

BioNTech’s Radical Overhaul: 1,860 Job Cuts, Factory Shutdowns, and a €532 Million Loss as Cancer Bet Takes Center Stage

SiterGedge by SiterGedge
May 11, 2026
in Earnings, Pharma & Biotech, TecDAX
0
BioNTech Stock
0
SHARES
72
VIEWS
Share on FacebookShare on Twitter

The era of pandemic-era blockbuster revenues at BioNTech has come to a definitive end. The Mainz-based biotech is shuttering four production sites – including its flagship plants in Marburg, Idar-Oberstein, and Tübingen, along with its Singapore facility – and shedding roughly 1,860 of its 8,400 employees by 2027. The complete halt of COVID-19 vaccine manufacturing by 2026 marks the most aggressive restructuring since the company shot to global prominence.

The financial toll of that transition was laid bare in the first quarter. Revenue slumped to €118.1 million from €183 million a year earlier, as demand for mRNA jabs continues to evaporate. BioNTech booked a net loss of nearly €532 million, translating to an adjusted loss of $2.26 per American depositary share – a figure that nonetheless came in slightly better than analyst forecasts.

Management is not standing idle. The board reaffirmed its full-year revenue target of roughly €2 billion and announced a $1 billion share buyback program. That signal of confidence is backed by a formidable war chest: nearly €17 billion in cash and equivalents, a cushion that allows the company to fund its pivot without immediate financing worries.

Wall Street is split on whether the bet will pay off. Goldman Sachs and Wells Fargo retain buy ratings, but Canaccord slashed its price target to $158 after the quarterly numbers. Leerink Partners is even more bearish, having cut its target to $94 in April, citing doubts about the phase 3 trial for the cancer candidate Gotistobart. Meanwhile, research and development spending surged to €557 million last quarter, much of it directed toward the oncology pipeline and the integration of CureVac assets acquired last year.

Should investors sell immediately? Or is it worth buying BioNTech?

Boardroom turbulence adds another layer of uncertainty. Co-founders Uğur Şahin and Özlem Türeci are stepping down as CEO and chief medical officer, respectively, at year-end. Market watchers say a strong successor could inject fresh momentum, but the transition also opens the door to strategic drift. In a separate move that caught some investors’ attention, Chief Operating Officer Sierk Poetting sold 50,000 shares in April, netting about $5.5 million under a preset trading plan.

The stock has felt the weight of these crosscurrents. BioNTech closed at €79.45 on Friday, down nearly 10% year to date and languishing below its 200-day moving average. Yet when the restructuring news broke on Monday, the shares bounced 2.2% to €81.20, a level that is now testing the 50-day line at €82.74. Chart technicians view a decisive break above that threshold as an early technical vindication of the new strategy.

The next catalyst arrives at the end of May, when BioNTech will present phase 2 data for its non-small cell lung cancer candidate Pumitamab at the ASCO conference. The company is also advancing Pumitamig and recently unveiled phase 2 results for Trastuzumab Pamirtecan in a form of uterine cancer. These readouts will provide the most concrete evidence yet that the oncology pivot can deliver. With several billion euros required to bring a new cancer drug to market, the industry-wide shift toward oncology and immunology among German pharma players makes BioNTech’s high-stakes transformation a closely watched test case.

Ad

BioNTech Stock: Buy or Sell?! New BioNTech Analysis from November 18 delivers the answer:

The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 18.

BioNTech: Buy or sell? Read more here...

Tags: BioNTech
SiterGedge

SiterGedge

Related Posts

Nvidia Stock
AI & Quantum Computing

Nvidia’s Insider Sales and $12.9 Billion Acquisition Paint a Portrait of a Company in Overdrive

September 7, 2026
Novo Nordisk Stock
Analysis

Novo Nordisk Faces a New Front: 300-Fold Rise in GLP-1 Scripts for Children Under 12

September 7, 2026
DroneShield Stock
Analysis

DroneShield’s European Ambitions Face Off Against an Unresolved ASIC Probe

September 7, 2026
Next Post
MSCI World ETF Stock

Overbought and Overexposed: The MSCI World ETF Navigates a New Fed and Pharma Tariffs

Software's Efficiency Purge: Record Earnings, Fewer Employees

Software's Efficiency Purge: Record Earnings, Fewer Employees

Siemens Stock

Siemens Flips the Switch on a Microgrid Milestone as Energy Tailwinds Propel Shares Toward Record High

Recommended

aTyr Pharma Stock

Make or Break Moment Approaches for aTyr Pharma

1 year ago
Battalion Oil Stock

Battalion Oil: Record-Breaking Wells in the Permian, But a Shelf Filing Casts a Long Shadow

7 months ago
IonQ Stock

IonQ Posts 755% Q1 Revenue Jump as Quantum Security Product Hits the Market

5 months ago
Stryker Stock

Analyst Confidence and Insider Activity Signal Strength for Stryker

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

A Hot CPI Reading Stalls the Rebound and Puts a December Hike in Play

Cash Over Stories: Take-Two, Cisco and Nvidia Face Their Tests

Trending

Nvidia Stock
Newsletter

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

by Stephanie Dugan
November 18, 2026
0

Dear readers, Nvidia reported the best quarter in its history, according to the company, and the founder...

Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026
Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026
Cisco Stock

At 5.15%, the 10-Year Treasury Picks the Winners

November 14, 2026
Bitcoin Stock

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

November 13, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone
  • Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers
  • Rotation, Not Panic: Retailers Test Where Tech’s Money Went

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com